Überblick über unsere Studien.
Laufende Studien:
A Phase 3 Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease.
I6T-MC-AMAX
A randomized, double-blind, placebo-controlled, parallel group, multicenter, 24-week study investigating the efficacy and safety of secukinumab compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy and failure to conventional therapy “UnchAIN”
CAIN457FDE05
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
mRNA-1647-P301
ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
EX6018-4758
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficiency and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes (SURPASS-EARLY)
I8F-MC-GPHE
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching from Weekly Dulaglutide to Weekly Tirzepatide in Adults with Type 2 Diabetes
I8F-MC-GPIH
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
J2A-MC-GZGQ
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
J2A-MC-GZGS
Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years (E.mbrace)
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
I8F-MC-GPGN
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
NN9388-4896
Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes
EX9924-4473
Efficacy and safety of oral Semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4)
NN9932-4954
Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifiying Therapies
TA-8995-304
A Master Protocol to Investigate the Efficacy and Safety of Trizepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
I8F-MC-GPIF
Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity
NN9536-4999
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naive Adults with Type 2 Diabetes
I8H-MC-BDCX
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease
NN9838-4942
Abgeschlossene Studien:
Kooperationsprojekt mit dem VDBD und der Universitätsklinik Jena Entwicklung und Evaluation eines Schulungsprogramms für Angehörige von Menschen mit Diabetes mellitus (Finanzielle Förderung aufgrund eines Beschlusses des Bundestages durch die Bundesregierung).
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults≥60 Years of Age
RSV-MVA-004
A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin. COMBINE 3
NN1535-4593
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) with or without Metformin
I8F-MC-GPHD
Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity
NN9932-4737
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily injections
I8H-MC-BDCV
SELECT – Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
EX9536-4388
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes
NN9924-4635
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease
I6T-MC-AMAM
Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting
NN1436-4481
Pemafibrate to reduce cardiovascular outcomes by reducing Triglycerides In patients with diabetes (PROMINENT)
K-877-302
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
I8H-MC-BDCL
A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus
LPS14947
A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus
H9X-MC-GBGC
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
I88-MC-ITSB
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older
QHD00011
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 DiabetesPatients at High Cardiovascular Risk
EFC14828
A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or without Metformin (SURPASS-5)
I8F-MC-GPGI
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
EFC-14875
A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Basal Insulin Treated Subjects With Type 2 Diabetes Mellitus
NN1436-4466
Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes
NN9535-4386
A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in insulin-naïve subjects with type 2 diabetes mellitus
NN1436-4465
A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
I8B-MC-ITRO
A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a ficed ratio combination single-arm 26-week etnsion period.
EFC 13794
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D
PRONTO-T2D
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Arm, in Combination with Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes PRONTO-T1D
PRONTO-T1D
A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 Diabetes Mellitus
D5670C00004 MEDI 0382
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period
EFC 15081
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)
D3250C00045
A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)
ESR-16-12160/UKE-DapEx-001
Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52 – week randomised, double-blind, active-and placebo-controlled trial
NN9924-4224
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes
NN9924-4221
A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone, followed by a ficed ratio combination single-arm 26-week extesion period
EFC 13794
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period
EFC 15081
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes
NN1218-4101
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus
H9X-MC-GBGE
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus-Study Two
MB 102230
A21-week, open-label, randomized,controlled, parallel-group, multi-center study evaluating the efficacy and safety of HOE901-U300 administered according to a device-supported treat-to-target regimen versus routine titration in T2DM patients
HOE901-EFC13470
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
LPS14355
A twenty- six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naive patients with uncontrolled type 2 diabetes mellitus, with 6-month extension
LPS 13931
A Randomized, Open Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy
LPS 14354
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budenoside/formoterol) Turbohaler 160/4,5 µg “as needed” compared with Pulmicort (budenoside) Turbohaler 0,4 mg “as needed”.
D589SC00003
A 52-week, multi-centre, randomised, parallel-group, double-blind, active-controlled, phase IV study to evaluate the safety and efficacy of Dapagliflozin or Dapagliflozin plus Saxagliptin compared with Sulfonylurea all given as add-on therapy to Metformin in adult patient with type 2 diabetes who have inadequate control on Metformin monotherapy
D1689C00014
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus
Development and Evaluation
MB102-229
„Development and Evaluation of an evidence-based shared making programme for prevention of myocardial infarction in type 2 diabetes“ Projektleitung: Dr. phil. Matthias Lenz, Universität Hamburg, Fachbereich Gesundheitswissenschaften.
Diabetesversorung im ländlichen Raum. Ein Versorgungsforschungsprojekt zum Einfluss der Betreuung durch Diabetesberater in strukturschwachen Gebieten auf die Versorgungsqualität von Menschen mit Diabetes
A long-term, randomized, double-blind, placebo-controlled, multinational- multi-centre trial to evaluate cardiovascular and other long term outcomes with semaglutide in subjects with type 2 diabetes. Trial phase: 3a.
NN9535-3744
Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.
NN9535-3624
LEADER™ (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results). Along-term, multicentre, international, randomised, double-blind, placebo-controlled, phase 3b trial – 2010
A randomized, open-label,2-arm parallel-group, multicenter, 26-week study assessing the safety and efficacy of HOE901-U300 versus Lantus in older patients with type 2 diabetes inadequately controlled on antidiabetic regimes either including no insulin, or with basal insulin as their only insulin
EFC13799 SENIOR
Onset1. Efficacy and safety of FiAsp compared to insulin aspart both in combination with insulin detemir in adults with type 1 diabetes.
NN1218-3852
Eine multizentrische, doppelt-blind, aktivkontrollierte Parallelgruppenstudie zur Untersuchung der Wirksamkeit und Verträglichkeit von LCZ696 gegenüber Enalapril in Hinblick auf Morbidität und Mortalität bei Patienten mit chronischer Herzinsuffizienz und reduzierter Ejektionsfraktion – Abgeschlossen seit 2014
CLCZ696B2314
A randomized study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic control on their current sulfonylurea monotherapy.
CLAF237ADE08
The effect of liraglutide when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes. A 26-week double-blind placebo-controlled randomized multicentre, multinational parallel-group trial.versus placebo
NN2211-3917
Prävalenz gestörter Atmung im Schlaf bei Patienten mit Beinvenenthrombose / Lungenembolie. Eine prospektive multizentrische Querschnittsuntersuchung der AG Kreislauf und Schlaf der DGSM – 2009
TRANS-North study
Phase III, double-blind, placebo controlled, parallel group, international, multicenter studie of 12 weeks treatment with trafermin 0,01% spray in patients with diabetic foot ulcer of neuropathic origin. 2011 – 2012